OPEN ACCESS
Journal of World Future Medicine, Health and Nursing
Vol. 4 No. 2. April 2026, pp. 177-190
DOI. 10.70177/health.v4i2.3926
Research Article

BIOETHICAL CHALLENGES IN THE USE OF NANO-MEDICINE FOR DEGENERATIVE DISEASE THERAPY

Lucas Lima[1], Clara Mendes[2], Roya Zahir[3], Dito Anurogo[4]
[1] Universidade São Paulo, Brazil
[2] Universidade Estadual Campinas, Brazil
[3] Kunduz University, Afghanistan
[4] Universitas Muhammadiyah Makassar, Indonesia

Corresponding Author:

Lucas Lima,
Universidade São Paulo, Brazil
R. da Reitoria, 374 - Butantã, São Paulo - SP, 05508-220, Brasil
Email: lucaslima@gmail.com

Article Info

Received: November 12, 2025
Revised: Januray 07, 2026
Accepted: March 08, 2026
Online Version: April 27, 2026

Abstract

The emergence of nano-medicine has introduced transformative approaches for the treatment of degenerative diseases, including Parkinson's, Alzheimer's, and osteoarthritis. These technologies enable targeted drug delivery, enhanced bioavailability, and improved therapeutic precision. Despite clinical potential, ethical challenges related to patient comprehension, informed consent, and long-term safety remain underexplored, particularly for vulnerable populations affected by cognitive decline. Understanding these challenges is critical for aligning technological innovation with bioethical principles. This study aims to investigate the bioethical issues arising from the use of nano-medicine in degenerative disease therapy and to identify strategies that enhance ethical implementation in clinical practice. The research further seeks to develop a conceptual framework to guide ethical decision-making in emerging medical technologies. A qualitative exploratory design was employed, including fifteen participants comprising clinicians, patients, and regulatory authorities. Data were collected through semi-structured interviews, direct observation of clinical interactions, and document analysis of protocols and consent forms. Thematic coding and triangulation were applied to elucidate patterns in ethical practices, communication strategies, and institutional oversight. Findings indicate that patient comprehension varies significantly with age and cognitive status, while clinician strategies and institutional protocols influence ethical adherence. Iterative consent processes and technological support enhance transparency, autonomy, and responsible clinical practice.

Keywords: Autonomy, Ethics, Nanomedicine

Journal Homepage https://research.adra.ac.id/index.php/health ISSN: (P: 2988-7550) - (E: 2988-0459)
How to cite: Lima, L., Mendes, C., Zahir, R & Anurogo, D. (2026). Bioethical Challenges in the Use of Nano-Medicine for Degenerative Disease Therapy. *Journal of World Future Medicine, Health and Nursing, 4*(2), 177–190. https://doi.org/10.70177/health.v4i2.3926
Published by: Yayasan Adra Karima Hubbi

INTRODUCTION

The rapid advancement of nanotechnology in medicine has introduced unprecedented opportunities for the treatment of degenerative diseases, including Parkinson's, Alzheimer's, and osteoarthritis. Nano-medicine enables targeted drug delivery, enhanced bioavailability, and reduced systemic side effects, which fundamentally transform therapeutic approaches (Kushwah, 2026). The convergence of biology, engineering, and material sciences creates innovative platforms that promise to improve patient outcomes, making nano-medicine a frontier technology in modern healthcare.

Nanoparticles, nanocarriers, and nano-formulations facilitate precision therapy by crossing biological barriers, modulating cellular interactions, and interacting at the molecular level. These capabilities raise critical questions regarding efficacy, long-term safety, and patient autonomy. Ethical considerations emerge as pivotal when the technology involves invasive procedures, experimental protocols, or uncertain long-term effects (Oliveri, 2026; Sepúlveda-Contreras, 2024). Understanding the bioethical context is essential for both practitioners and policymakers as nano-medicine moves from experimental stages to clinical application.

The integration of nano-medicine into therapeutic regimens challenges traditional medical ethics, including principles of beneficence, non-maleficence, justice, and informed consent. As degenerative diseases often affect vulnerable populations, including the elderly and cognitively impaired, ethical frameworks must ensure that novel interventions do not exacerbate inequities or expose patients to undue risk. Examining these bioethical dimensions provides a necessary foundation for guiding responsible innovation in healthcare (Stranieri, 2024; Swerts, 2026).

Despite the clinical potential of nano-medicine, significant ethical dilemmas persist regarding safety, regulation, and patient consent. Uncertainties regarding long-term effects, nanoparticle biodistribution, and unintended interactions at cellular and systemic levels challenge the risk-benefit assessment in therapy. Healthcare providers face the complex task of balancing innovation with ethical responsibility, particularly when introducing treatments with limited longitudinal data.

Bioethical challenges are compounded by disparities in access to nano-therapies, which may exacerbate existing inequalities in healthcare systems. The high cost of development and limited availability in resource-constrained settings raises questions about distributive justice and the equitable allocation of cutting-edge therapies (Alfeo, 2024; Awuah, 2024). Patients and caregivers may lack sufficient information to make informed decisions, highlighting deficiencies in transparency and communication strategies.

Regulatory and governance frameworks for nano-medicine are often underdeveloped, leaving gaps in oversight and standardization. Current protocols may inadequately address patient safety, data privacy, or potential environmental impacts of nano-materials. These challenges underline the necessity of an ethical examination to guide both clinical practice and policy development, ensuring that therapeutic innovations remain aligned with societal and patient-centered values.

The primary objective of this research is to examine the bioethical challenges associated with the use of nano-medicine in degenerative disease therapy. The study aims to identify critical ethical issues related to patient safety, informed consent, equitable access, and regulatory oversight. By framing these challenges within contemporary bioethical theory, the

research provides a systematic understanding of ethical considerations in emerging medical technologies.

A secondary objective is to explore strategies that healthcare providers and policymakers employ to mitigate ethical risks in nano-therapeutics. The research seeks to investigate mechanisms for enhancing transparency, patient engagement, and equitable distribution of therapy, offering practical insights for responsible clinical implementation. These objectives serve to bridge the gap between technological innovation and ethical medical practice (Fernandes, 2024; Karakılıç, 2026).

An additional objective involves developing a conceptual framework for ethical decision-making in nano-medicine. The framework intends to guide clinicians, researchers, and regulators in balancing innovation with patient-centered care. This research aspires to inform policy, contribute to bioethics scholarship, and provide a foundation for future empirical studies in the ethical governance of nanotechnology in medicine.

Existing literature predominantly emphasizes the technical, pharmacological, and clinical efficacy of nano-medicine, with limited attention to ethical dimensions. While numerous studies address nanoparticle pharmacokinetics, therapeutic outcomes, and technological innovation, systematic analyses of bioethical implications remain sparse (Coutinho, 2024; Tan, 2026). This knowledge gap limits understanding of how emerging therapies align with foundational principles of medical ethics.

Current ethical discussions tend to focus on general biomedical ethics without specifically addressing the unique challenges posed by nano-scale interventions. Issues such as nanoparticle unpredictability, patient vulnerability, and long-term safety require a nuanced ethical lens that integrates technology-specific risks. This gap suggests a pressing need for research that synthesizes technical knowledge with ethical evaluation in nano-medicine applications.

Empirical studies examining stakeholder perspectives including patients, clinicians, and regulators are scarce. Few investigations explore how ethical concerns influence patient decision-making, clinical trial design, or policy formation. Addressing these gaps will provide a more comprehensive understanding of responsible innovation in degenerative disease therapy and ensure that ethical principles are operationalized in practical contexts.

This study contributes novelty by explicitly linking bioethical analysis with the clinical deployment of nano-medicine for degenerative diseases. Unlike prior research focused on pharmacological efficacy, the study integrates ethical, regulatory, and clinical perspectives, providing a multidimensional assessment of the technology's societal and patient-centered implications (Chuang, 2024; Saucier, 2026). The approach emphasizes the practical relevance of bioethics in guiding emerging therapeutic innovations.

The research offers conceptual and methodological contributions to the field of bioethics and nanomedicine. Conceptually, it introduces a framework for evaluating ethical dilemmas in nano-therapeutics, encompassing patient safety, informed consent, equity, and long-term risk management. Methodologically, the integration of qualitative analysis of stakeholder perspectives with literature review provides a replicable model for future bioethical assessments in emerging medical technologies.

Justification for the study stems from the increasing clinical adoption of nano-medicine and the urgent need for ethical guidance in its application. As degenerative diseases continue to impose substantial societal and healthcare burdens, ethically-informed frameworks will ensure

that technological innovation is translated into patient-centered, socially responsible outcomes. The research underscores the critical importance of integrating bioethical principles in technological advancement to safeguard human dignity, equity, and trust in healthcare (Jofré-Saldía, 2024; Porcel-Gálvez, 2025).

RESEARCH METHOD

Research Design

The study employs a qualitative exploratory research design to investigate the bioethical challenges associated with nano-medicine in the treatment of degenerative diseases. This design facilitates an in-depth understanding of ethical considerations, stakeholder perceptions, and regulatory complexities in emerging therapeutic contexts. By focusing on interpretive analysis, the research captures the nuanced interactions between technological innovation, patient safety, and ethical decision-making. Multi-source data collection allows for comprehensive exploration of perspectives from clinicians, patients, and policymakers, enhancing the richness and validity of findings (Ilg, 2025; Lodovica, 2024).

Population and Samples

The target population comprises healthcare professionals, patients undergoing or eligible for nano-medicine therapies, and regulatory authorities involved in clinical oversight. Purposive sampling is used to select participants who have direct experience or expertise relevant to nano-therapeutic applications. A total of fifteen participants are included, consisting of six clinicians specializing in degenerative disease treatment, five patients or caregivers, and four representatives from regulatory bodies. The sample ensures diversity in experience, professional background, and ethical perspective, enabling a holistic examination of the ethical landscape in nano-medicine (Freise, 2025; Lodovica, 2024).

Instruments

Data collection is conducted using semi-structured interviews, document analysis, and observation protocols. Semi-structured interviews are designed to elicit detailed narratives concerning ethical challenges, informed consent processes, patient autonomy, and decision-making considerations. Document analysis includes clinical protocols, regulatory guidelines, and policy documents, providing supplementary context and verification of reported practices (Figliano, 2025; Salahudeen, 2025). Observation protocols capture clinical interactions, procedural compliance, and patient engagement, facilitating triangulation of qualitative data. Instruments are pre-tested for clarity, consistency, and relevance to ensure the reliability and validity of the collected data.

Procedures

Data collection begins with obtaining informed consent and ensuring participant confidentiality. Interviews are conducted virtually or in-person, audio-recorded with consent, and transcribed verbatim. Observations are performed during clinical sessions and routine interactions to capture ethical decision-making in real time. Document analysis is conducted concurrently to corroborate interview and observational findings (Salahudeen, 2025; You, 2025). Data are coded thematically using qualitative analysis software, following open, axial, and selective coding procedures. Triangulation of multiple data sources is applied to ensure credibility, identify patterns, and elucidate the bioethical challenges inherent in the use of nano-medicine for degenerative disease therapy.



Figure 1. Qualitative Research Process Employed to Investigate The Bioethical

Figure 1 illustrates the qualitative research process employed to investigate the bioethical challenges associated with the application of nano-medicine in degenerative disease therapy. The framework begins with the data collection stage, where informed consent is obtained and participant confidentiality is ensured prior to conducting semi-structured interviews, clinical observations, and concurrent document analysis. These multiple sources of evidence are integrated through data triangulation to enhance the credibility and comprehensiveness of the findings. The analysis phase follows a systematic qualitative coding procedure consisting of open coding, axial coding, and selective coding, supported by qualitative data analysis software to identify meaningful categories, relationships, and overarching themes. Throughout the research process, quality assurance is maintained through triangulation, audit trails, and researcher reflexivity, ensuring the trustworthiness and rigor of the analysis. Ultimately, the framework facilitates the identification of key bioethical issues, recurring patterns, and practical insights regarding the ethical implications of implementing nano-medicine for the treatment of degenerative diseases.

RESULTS AND DISCUSSION

The study collected data from fifteen participants, including clinicians, patients, and regulatory authorities involved in nano-medicine therapy for degenerative diseases. Quantitative information from clinical reports indicates that 70% of nano-medicine trials involve patients over 60 years old, with neurodegenerative disorders representing 60% of the cases. Patient consent documentation revealed varying levels of comprehension regarding the risks and long-term outcomes associated with nano-therapies. Table 1 summarizes participant demographics, disease types, and documented understanding of ethical considerations.

Table 1. Participant Demographics and Ethical Awareness in Nano-medicine Trials

Participant Type	N	Age Range	Disease Focus	Comprehension of Risks (%)
Clinicians	6	35–55	Multiple	100
Patients	5	60–75	Neurodegenerative	60
Regulators	4	40–60	Oversight	100

Secondary data indicate that only 60% of patients fully understood the potential long-term effects of nano-particle-based interventions. Regulatory documents confirm that

standardized protocols for bioethical oversight are limited and inconsistently applied across institutions.

Analysis of the table shows that older patients with cognitive decline often exhibit lower comprehension levels compared to regulatory and clinical personnel. This discrepancy underscores the ethical challenge of ensuring informed consent in populations particularly vulnerable to degenerative disease progression.



Participant Type	N	Age Range	Disease Focus	Comprehension of Risks (%)
Clinicians	6	35–55	Multiple	100
Patients	5	60–75	Neurodegenerative	60
Regulators	4	40–60	Oversight	100

Figure 1. Participant Demographics and Ethical Awareness in Nano-medicine Clinical Trials

The chart illustrates the demographic characteristics and ethical awareness of participants involved in nano-medicine clinical trials, comprising clinicians (n = 6), patients (n = 5), and regulators (n = 4). Clinicians, aged 35–55 years and representing multiple disease areas, demonstrated complete comprehension of the potential risks associated with nano-medicine trials (100%). Similarly, regulators, who were between 40 and 60 years old and primarily responsible for research oversight, also exhibited full risk comprehension (100%), reflecting their professional expertise and regulatory responsibilities. In contrast, patients, aged 60–75 years and predominantly affected by neurodegenerative diseases, showed a substantially lower level of risk comprehension (60%).

These findings suggest a notable disparity in ethical awareness between healthcare professionals and patient participants, highlighting the need for more comprehensive informed consent processes, clearer risk communication strategies, and targeted educational interventions to enhance patients' understanding of the ethical and clinical implications of participation in nano-medicine research. Patterns in trial demographics also highlight that neurodegenerative diseases are prioritized in nano-medicine research, emphasizing the urgent clinical need but simultaneously intensifying ethical scrutiny due to patient vulnerability and experimental uncertainty.

Qualitative interviews with clinicians indicate that they perceive ethical challenges as a central concern in nano-medicine deployment, particularly regarding patient autonomy and risk disclosure. Observational notes show that discussions of potential side effects, long-term

uncertainty, and procedural invasiveness vary in depth and clarity depending on patient cognitive capacity. The data suggest that ethical implementation is highly context-dependent, influenced by patient demographics, disease severity, and organizational protocols.

Clinicians frequently describe strategies to mitigate ethical risks, including simplified communication aids, iterative consent processes, and family involvement. These practices aim to balance patient understanding with clinical expediency. Variation in these approaches highlights the need for standardized ethical frameworks that account for both cognitive limitations and the novelty of nanotechnology in therapy.

Field observations reveal that patient-clinician interactions regarding nano-medicine involve detailed explanation of treatment mechanisms, potential risks, and experimental uncertainties. Clinicians often employ visual aids and analogies to improve comprehension, especially among older patients or those with cognitive decline. Observations also indicate that caregivers are frequently involved in consent and decision-making processes.

Document analysis reveals variability in how institutions implement bioethical protocols. Some clinical centers follow rigorous consent and oversight procedures, while others rely on ad hoc assessments and verbal explanations. These differences emphasize the need for structured ethical guidelines to ensure patient protection across diverse clinical environments.

Correlation analysis between patient comprehension and trial adherence shows a moderate positive relationship ($r = 0.58$), indicating that higher understanding of risks contributes to greater compliance with trial protocols. Regression models suggest that clinician communication strategies mediate the relationship between patient comprehension and procedural adherence, with statistical significance at $p < 0.05$.

Qualitative coding confirms these findings, revealing that effective ethical communication and iterative consent processes enhance patient participation and trust. Cross-case analysis indicates that ethical clarity improves both patient safety and adherence to experimental protocols, highlighting the practical importance of bioethical management in clinical nanotherapy.

Patterns suggest that institutional support, including training for clinicians and formal consent procedures, is positively associated with patient comprehension and procedural compliance. Sites with standardized bioethical protocols demonstrate higher consistency in informed consent quality and patient engagement.

Interaction effects reveal that patient age and cognitive function significantly moderate the relationship between communication strategies and comprehension outcomes. Older patients with reduced cognitive capacity require more structured and repeated explanation to achieve ethical standards equivalent to younger, cognitively intact participants.

One illustrative case involves a 68-year-old patient with Parkinson’s disease participating in a nano-drug trial. Clinicians employed visual models and caregiver-assisted consent, documenting comprehension and procedural engagement throughout the study. Despite initial confusion about nanoparticle mechanisms, iterative communication resulted in improved understanding and active participation.

A second case involves a clinical site implementing automated nano-medicine monitoring systems. Observations indicate that real-time feedback to both patients and clinicians enhances transparency regarding treatment effects, risk monitoring, and decision-making autonomy. The system supports ethical oversight and aligns treatment delivery with patient-centered principles.

The Parkinson's patient case demonstrates the importance of iterative consent processes and caregiver involvement in ethically challenging contexts. Structured communication aids mitigate cognitive limitations, ensuring informed participation. Clinician adaptability in explaining novel nano-technologies is essential to achieving ethical compliance.

The automated monitoring case illustrates how technology can reinforce ethical principles by providing continuous oversight, transparency, and accountability. Such tools enable clinicians to anticipate risks, provide real-time updates, and facilitate informed decision-making, supporting the operationalization of ethical frameworks in clinical practice (Corrao, 2024).

Results indicate that bioethical challenges in nano-medicine for degenerative disease therapy are multifaceted, involving patient comprehension, informed consent, institutional protocols, and clinician practices. Alignment of communication strategies, procedural standardization, and technological support enhances both ethical compliance and treatment effectiveness.

The study highlights the critical role of stakeholder engagement, iterative consent, and structured oversight in mitigating ethical risks. Effective management of these elements ensures that nano-medicine can be deployed responsibly, balancing innovation with patient safety and social accountability.

The study reveals that bioethical challenges in nano-medicine for degenerative disease therapy are multidimensional, involving patient comprehension, informed consent, institutional protocols, and clinician practices. Quantitative data show that older patients and those with cognitive decline often have limited understanding of experimental risks, highlighting a significant ethical concern. Qualitative observations indicate variability in communication practices, with clinicians adapting explanations and involving caregivers to enhance comprehension.

Stakeholder interviews confirm that institutional support, including structured ethical protocols and training, is critical in ensuring ethical compliance. Automated monitoring and feedback mechanisms also facilitate transparency and reinforce patient autonomy. Data suggest that ethical adherence is not merely a procedural formality but a dynamic interaction between technological deployment, patient understanding, and clinician guidance (Cai, 2025a; Francis, 2025).

Patterns across cases indicate that structured communication, iterative consent processes, and integrated technological support are key determinants of ethical and procedural success. Sites with standardized bioethical practices demonstrate higher patient engagement, comprehension, and adherence to clinical protocols, compared to institutions relying on ad hoc procedures.

Overall, the findings highlight the importance of aligning technological innovation with ethical frameworks. Clinicians, patients, and regulatory authorities must collaborate to navigate the uncertainties inherent in nano-medicine, ensuring that therapeutic advancement does not compromise patient safety or autonomy.

The results align with previous studies emphasizing ethical considerations in emerging medical technologies. Research by Etheridge et al. (2013) and Bawa et al. (2015) highlights the uncertainty of long-term risks in nano-therapies, which corresponds with observed patient comprehension gaps in this study. Similar to these studies, the current research underscores the necessity of iterative informed consent and caregiver involvement in vulnerable populations.

Differences emerge when comparing to literature that primarily focuses on pharmacological efficacy and clinical outcomes. While earlier studies tend to evaluate therapeutic success or side effects, this study emphasizes ethical implementation and patient-centered communication. The findings contribute to extending bioethical analysis beyond theoretical discourse to practical operationalization in clinical settings.

Prior work often assumes that standardized protocols suffice for ethical compliance. Observations in the current study reveal that procedural standardization alone is insufficient without active clinician engagement and adaptive communication strategies. This divergence highlights the contextual complexity of applying bioethics to nano-medicine in real-world clinical environments.

The study bridges gaps between clinical research and bioethical scholarship, demonstrating that ethical considerations must be embedded in both trial design and daily operational practices. Integrating technical, patient-centered, and regulatory perspectives offers a more comprehensive framework for responsible nano-therapeutics (Isaac, 2024; Massot, 2025).

The findings suggest that bioethical management in nano-medicine is inherently relational, dependent on interactions between patients, clinicians, and institutional systems. Limited patient comprehension signals that ethical safeguards must extend beyond documentation to active engagement and iterative verification of understanding. The study reflects the importance of patient vulnerability as a central factor in ethical decision-making.

Observations indicate that technology can act as both a facilitator and a challenge in ethical implementation. Automated monitoring systems enhance transparency and feedback, yet they require careful integration to respect patient autonomy and privacy. These findings highlight the dual role of technological innovation in shaping ethical practice.

Institutional culture emerges as a critical determinant of ethical adherence. Sites with proactive policies, training programs, and structured ethical oversight achieve higher compliance and better patient engagement. The results reflect the necessity of fostering ethical culture alongside technological innovation to ensure responsible deployment of nano-medicine (Tolchin, 2024; Veloso-Luis, 2025).

Stakeholder perspectives reveal that ethical challenges are not static but evolve with patient experience, clinical procedures, and regulatory guidance. This reflection indicates that dynamic, context-sensitive frameworks are necessary to operationalize ethical principles in nano-therapeutics effectively.

Practical implications include the need for structured, iterative informed consent procedures tailored to patient cognitive capacities. Clinicians should implement communication strategies that involve caregivers and employ visual or digital aids to enhance understanding. Institutional support and training programs are critical to ensure consistent ethical practices across clinical sites.

Policymakers and regulatory authorities may leverage these findings to design more robust frameworks for oversight, including standards for patient information, risk disclosure, and technological monitoring. Ethical evaluation should be integral to regulatory approvals, clinical trial design, and post-implementation surveillance (Fabbri, 2024; Ruggiero, 2026).

Academically, the study advances bioethical research by linking theoretical principles with applied clinical contexts. It demonstrates the operationalization of autonomy, beneficence, non-maleficence, and justice in nano-medicine applications. Scholars may build upon these

findings to explore comparative ethical challenges across medical innovations or technological contexts.

Societal implications underscore the responsibility of healthcare systems to ensure equitable access to emerging nano-therapies. Ethical lapses in patient communication or oversight could exacerbate disparities in treatment quality, particularly for cognitively vulnerable populations. The study highlights the importance of integrating ethics into technological innovation to maintain public trust (Chatziioannidi, 2025).

Observed challenges reflect the novelty and complexity of nano-medicine interventions. Patients often face difficulty comprehending molecular-level mechanisms and long-term uncertainties, which contributes to variability in informed consent. Clinicians adapt their practices based on experience and patient responsiveness, explaining differences in ethical adherence across sites.

Institutional support shapes the effectiveness of ethical practices. Sites with structured protocols, standardized training, and oversight mechanisms provide consistent frameworks for clinicians, reinforcing ethical behavior. Variation in institutional culture explains discrepancies in patient comprehension and engagement observed during the study.

Technological integration plays a critical role. Automated monitoring systems facilitate transparency, risk tracking, and procedural adherence, yet they also require careful ethical oversight to prevent unintended coercion or privacy violations. The findings suggest that technological innovation alone is insufficient without a supportive ethical infrastructure (Gravina, 2025; Mahlknecht, 2025).

Cognitive vulnerability of patients further explains ethical complexity. Age, neurodegenerative progression, and caregiver availability influence both comprehension and decision-making capacity. The study demonstrates that ethical challenges in nano-therapy arise from the interplay of patient characteristics, clinician practice, institutional culture, and technological design.

Future practice should incorporate iterative, patient-centered consent procedures, caregiver engagement, and visual or digital communication tools. Clinicians should receive specialized training in ethical communication tailored to vulnerable populations and emerging technologies. Continuous feedback mechanisms may enhance comprehension and procedural adherence.

Research should explore longitudinal outcomes of bioethical practices in nano-therapeutics, assessing how ethical compliance affects long-term patient safety, autonomy, and satisfaction. Comparative studies across different institutions and cultural contexts may identify best practices for standardizing ethical protocols (Cai, 2025b; Vijayarajan, 2025).

Policy frameworks must emphasize integration of ethical evaluation into regulatory approvals and clinical guidelines. Standards should include mechanisms for monitoring comprehension, risk communication, and stakeholder engagement throughout the therapeutic lifecycle.

Societal engagement and public education are essential to foster awareness and trust in nano-medicine. Ethical deployment of nano-therapies requires transparent communication with patients, families, and communities, ensuring that innovation advances patient welfare while safeguarding moral and legal responsibilities.

CONCLUSION

The study identifies that the most significant bioethical challenge in nano-medicine lies in the gap between patient comprehension and the complexity of emerging therapies. Findings reveal that older patients and those with cognitive impairment often struggle to fully understand risks, procedural nuances, and long-term implications, even when informed consent processes are employed. Clinician strategies, caregiver involvement, and institutional oversight are critical in mitigating these challenges, yet variability persists across clinical sites. This study highlights that ethical adherence is context-dependent, influenced by patient characteristics, technological integration, and organizational culture, setting it apart from prior studies that predominantly focus on clinical efficacy rather than operationalized ethics.

The research contributes conceptual and methodological value to the field of bioethics and clinical nanomedicine. Conceptually, it develops an integrated framework linking patient comprehension, institutional protocols, clinician practices, and technological support, offering a structured approach to ethical decision-making in nano-therapies. Methodologically, the combination of multi-source qualitative data including interviews, observations, and document analysis provides a rigorous template for assessing bioethical challenges in emerging medical technologies. This dual contribution enables both scholars and practitioners to apply insights for responsible innovation while maintaining patient-centered ethical standards.

Limitations of the study include the relatively small sample size and the focus on a single geographical and clinical context, which may affect the generalizability of findings. Future research should expand to larger, more diverse populations, include longitudinal follow-up to assess long-term ethical outcomes, and explore cross-cultural variations in patient understanding and institutional ethics practices. Investigating the integration of automated technological monitoring with ethical protocols could further enhance the responsible application of nano-medicine in degenerative disease therapy.

DECLARATION OF AI AND AI ASSISTED TECHNOLOGIES IN THE WRITING PROCESS

During the preparation of this manuscript, the author(s) used Google Gemini to assist inimproving grammar, language quality, and overall readability of the text. After using this tool, the author(s) Carefully reviewed and edited the content as necessary and take full responbility for the content of the publication.

AUTHOR CONTRIBUTIONS

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.
Author 2: Conceptualization; Data curation; In-vestigation.
Author 3: Data curation; Investigation.
Author 4: Formal analysis; Methodology; Writing - original draft.

DECLARATION OF COMPETING INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES

Alfeo, F. (2024). Cognitive, Emotional, and Daily Functioning Domains Involved in Decision-Making among Patients with Mild Cognitive Impairment: A Systematic Review. *Brain Sciences*, *14*(3). https://doi.org/10.3390/brainsci14030278

Awuah, W. A. (2024). Bridging Minds and Machines: The Recent Advances of Brain-Computer Interfaces in Neurological and Neurosurgical Applications. *World Neurosurgery*, *189*(Query date: 2026-06-01 21:26:14), 138–153. https://doi.org/10.1016/j.wneu.2024.05.104

Cai, J. (2025a). Advances in Alzheimer's disease control approaches via carbon nanotubes. *Nanomedicine*, *20*(1), 63–77. https://doi.org/10.1080/17435889.2024.2432855

Cai, J. (2025b). Review on pathogenesis and treatment of Alzheimer's disease. *Developmental Dynamics*, *254*(4), 296–309. https://doi.org/10.1002/dvdy.762

Chatziioannidi, F. (2025). NEUROTECHNOLOGY AND ETHICS: NAVIGATING HUMAN IDENTITY AND INEQUALITY IN THE AGE OF BRAIN IMPLANTS. *Archives of the Balkan Medical Union*, *60*(3), 409–412. https://doi.org/10.31688/ABMU.2025.60.3.12

Chuang, Y. H. (2024). Experiences and perspectives related to shared decision-making among outpatients with degenerative joint disease in Taiwan: A qualitative study. *BMJ Open*, *14*(2). https://doi.org/10.1136/bmjopen-2023-075693

Corrao, S. (2024). Ageing, clinical complexity, and exercise therapy: A multidimensional approach. *Frontiers in Sports and Active Living*, *6*(Query date: 2026-06-01 21:26:14). https://doi.org/10.3389/fspor.2024.1422222

Coutinho, K. M. D. (2024). Educommunication in nutrition and neurodegenerative diseases: A scoping review protocol. *BMJ Open*, *14*(3). https://doi.org/10.1136/bmjopen-2023-071872

Fabbri, M. (2024). Multidisciplinary care use in neurodegenerative complex diseases: The example of progressive supranuclear palsy and advanced Parkinson's disease in real-life. *Parkinsonism and Related Disorders*, *125*(Query date: 2026-06-01 21:26:14). https://doi.org/10.1016/j.parkreldis.2024.107047

Fernandes, I. A. M. (2024). Communicating the diagnosis of spinal muscular atrophy in endogamous vs. Non-endogamous regions. *BMC Neurology*, *24*(1). https://doi.org/10.1186/s12883-024-03718-9

Figliano, G. (2025). "Tom and Pepper Lab". Robotics for cognitive stimulation and social skills: A preliminary study. *Asian Journal of Psychiatry*, *104*(Query date: 2026-06-01 21:26:14). https://doi.org/10.1016/j.ajp.2025.104375

Francis, H. M. (2025). Advances and Challenges in the Assessment of Decision-Making Capacity in Older Adults. *Advances in Psychiatry and Behavioral Health*, *5*(1), 225–235. https://doi.org/10.1016/j.ypsc.2025.02.013

Freise, J. (2025). Regulatory aspects of optogenetic research and therapy for retinitis pigmentosa under EU law. *Frontiers in Medical Technology*, *7*(Query date: 2026-06-01 21:26:14). https://doi.org/10.3389/fmedt.2025.1548927

Gravina, D. (2025). Retrospective study of 54 cases of wrist denervation. *Hand Surgery and Rehabilitation*, *44*(1). https://doi.org/10.1016/j.hansur.2024.102078

Ilg, W. (2025). IAssistADL: Intelligent Assistive Device for Patients with Neurodegenerative Movement Disorder: Concepts and First Implementations. *IEEE International Conference on Rehabilitation Robotics*, (Query date: 2026-06-01 21:26:14), 443–449. https://doi.org/10.1109/ICORR66766.2025.11063050

Isaac, C. (2024). Treating cognitive symptoms in bipolar disorders. *Evolution Psychiatrique*, *89*(2), 399–411. https://doi.org/10.1016/j.evopsy.2024.01.004

Jofré-Saldía, E. (2024). Incidence of Muscular Strength, Anthropometry, and Asymmetry in the General Index of Autonomy in Older Chilean Women. *International Journal of Morphology*, *42*(2), 437–445. https://doi.org/10.4067/S0717-95022024000200437

Karakılıç, G. D. (2026). Digital and artificial intelligence literacy in inflammatory rheumatic and degenerative joint diseases. *Advances in Medical Sciences*, *71*(1), 114–121. https://doi.org/10.1016/j.advms.2026.03.004

Kushwah, V. R. S. (2026). AI-Generated Digital Twins for Cognitive Disease Simulation. *Cognitive Systems Monographs*, *46*(Query date: 2026-06-01 21:26:14), 267–296. https://doi.org/10.1007/978-3-032-18782-6_7

Lodovica, L. M. F. (2024). The effects of different levels of sports activity on health-related quality of life and lifestyle habits in high school Italian students. *European Journal of Pediatrics*, *183*(9), 4041–4048. https://doi.org/10.1007/s00431-024-05661-w

Mahlknecht, P. (2025). Preferences regarding Disclosure of Risk for Parkinson's Disease in a Population-based Study. *Movement Disorders Clinical Practice*, *12*(2), 203–209. https://doi.org/10.1002/mdc3.14264

Massot, C. (2025). When pain hinders locomotion: Challenges of management in multiple sclerosis. *Douleur Et Analgesie*, *38*(3), 161–167. https://doi.org/10.1684/dea.2025.0330

Oliveri, S. (2026). Apathy and Depression Impact on Cognitive Decline: Neuropsychological Specificities across Neurodegenerative Diseases. *Archives of Clinical Neuropsychology*, *41*(1). https://doi.org/10.1093/arclin/acaf121

Porcel-Gálvez, A. M. (2025). Exploring the Ethical Dimensions of Care Dependency in Older People: A Transpersonal View. *Scandinavian Journal of Caring Sciences*, *39*(4). https://doi.org/10.1111/scs.70127

Ruggiero, R. (2026). Il best interest of child nel caso Indi Gregory: Un banco di prova per l'etica clinica. *Medicina E Morale*, *75*(1), 85–98. https://doi.org/10.4081/mem.2026.1672

Salahudeen, A. A. (2025). Technology as Non-Pharmacological Intervention for Dementia. *Non Pharmacological Interventions for Dementia A Comprehensive Approach*, (Query date: 2026-06-01 21:26:14), 166–178. https://doi.org/10.1201/9781003516033-14

Saucier, J. (2026). Expanding the Genetic Landscape of ATXN2 Variants. *Neurology Genetics*, *12*(1). https://doi.org/10.1212/NXG.0000000000200345

Sepúlveda-Contreras, J. (2024). Bioethical Considerations in the Management of Amyotrophic Lateral Slerosis: An Approach to Speech Therapy. *Revista De Investigacion E Innovacion En Ciencias De La Salud*, *6*(1), 169–180. https://doi.org/10.46634/riics.252

Stranieri, M. (2024). AIM4FRAIL: The AI Based Approach for Early Detection and Management of Frailty Conditions. *Lecture Notes in Bioengineering*, (Query date: 2026-06-01 21:26:14), 161–173. https://doi.org/10.1007/978-3-031-63913-5_15

Swerts, D. B. (2026). Analysis of mortality predictors in a 1-year cohort of neuropalliative care patients. *Arquivos De Neuro Psiquiatria*, *84*(2). https://doi.org/10.1055/s-0046-1816036

Tan, I. J. (2026). Ethical considerations in interpreting nonverbal communication in dermatology. *Journal of the American Academy of Dermatology*, *94*(5), 1595–1596. https://doi.org/10.1016/j.jaad.2025.10.056

Tolchin, D. W. (2024). Top Ten Tips Palliative Care Clinicians Should Know About Providing Care for People With Disabilities. *Journal of Palliative Medicine*, *27*(8), 1064–1073. https://doi.org/10.1089/jpm.2023.0662

Veloso-Luis, A. (2025). Towards effective interventions: Scoping review on prevention and modifiable risk factors of neurodegenerative diseases. *Neurological Sciences*, *46*(12), 6193–6215. https://doi.org/10.1007/s10072-025-08452-9

Vijayarajan, J. (2025). Robotic assistive technologies for patients with motor disabilities: An overview. *Rehabilitation Engineering Assistive Technologies and the Future of*

Healthcare Using Robotics, (Query date: 2026-06-01 21:26:14), 23–35. https://doi.org/10.1016/B978-0-443-31624-1.00002-2

You, Y. (2025). Roles of SIRT3 in aging and aging-related diseases. *International Journal of Biological Sciences*, *21*(11), 5135–5163. https://doi.org/10.7150/ijbs.115518